Abstracts tagged "remission"

Abstract Number: 1199 • 2018 ACR/ARHP Annual Meeting
The Use of Musculoskeletal Ultrasound to Assess Remission in Patients with Rheumatoid Arthritis
Myriam Allen¹, Maggie Larche² and Karen A. Beattie², ¹Rheumatology, McMaster University, Hamilton, ON, Canada, ²Medicine, McMaster University, Hamilton, ON, Canada
Background/Purpose: Patients with rheumatoid arthritis (RA) should achieve remission rapidly to avoid irreversible joint sequela. Studies have shown that patients with apparent clinical remission have…
Abstract Number: 167 • 2017 ACR/ARHP Annual Meeting
Differentially Co-Expressed Gene Networks in Previously DMARD-Naïve Patients with Early RA Achieving Sustained Drug-Free Remission after Step-up Methotrexate Therapy
Xavier M Teitsma¹, Johannes WG Jacobs¹, Michal Mokry², Attila Pethö-Schramm³, Michelle EA Borm⁴, Jacob M. van Laar⁵, Johannes W.J. Bijlsma⁶ and Floris PJ Lafeber⁵, ¹Department of Rheumatology & Clinical Immunology, University Medical Center Utrecht, Utrecht, Netherlands, ²Division of Pediatrics, University Medical Center Utrecht, Utrecht, Netherlands, ³F. Hoffmann-La Roche, Basel, Switzerland, ⁴Beneluxlaan 2a, Roche Nederland BV, Woerden, Netherlands, ⁵Rheumatology & Clinical Immunology, University Medical Center Utrecht, Utrecht, Netherlands, ⁶Rheumatology and Clinical Immunology, University Medical Center Utrecht, Utrecht, Netherlands
Background/Purpose: According to current standards, methotrexate (MTX) is an anchor drug in the treatment of rheumatoid arthritis (RA) and should be used in the initial…
Abstract Number: 439 • 2017 ACR/ARHP Annual Meeting
Analysis of Rheumatoid Arthritis Patients That Did Not Achieve the Treatment Goal By the Treat-to-Target Strategy in Daily Practice
Hideshi Yamazaki and Tetsuo Takanashi, Center for Rheumatic Disease, Marunouchi Hospital, Matsumoto, Japan
Background/Purpose: Although the goal of rheumatoid arthritis (RA) treatment is to achieve remission or low disease activity with the treat-to-target (T2T) strategy, some patients do…
Abstract Number: 460 • 2017 ACR/ARHP Annual Meeting
Usefullness of Serum Angiogenic and Proinflammatory Cytokines to Discriminate between 6 Sets of Remission Criteria and Biomarkers of Radiographic Progression and Clinical Flare in RA in Clinical Remission. Pre-Eliminary Results of a Study of 5 Years of Follow-up
Julio Ramírez¹, Andrea Cuervo², Raquel Celis³, Virginia Ruiz-Esquide¹, M. Victoria Hernández⁴, Raimon Sanmarti⁵ and Juan D. Cañete⁶, ¹Rheumatology Service, Hospital Clínic de Barcelona, Barcelona, Spain, ²Arthritis Unit. Rheumatology Dpt, Arthritis Unit, Rheumatology Dpt, Hospital Clinic of Barcelona and IDIBAPS, Barcelona, Spain, ³Rheumatology, Arthritis Unit, Barcelona, Spain, ⁴Hospital Clinic. Barcelona. Spain, Barcelona, Spain, ⁵Arthritis Unit, Rheumatology Dpt, Hospital Clinic of Barcelona, Barcelona, Spain, ⁶Rheumatology Department, Arthritis Unit, Rheumatology Dpt, Hospital Clinic of Barcelona, Barcelona, Spain
Background/Purpose: The primary aim of this study was to analyse serum levels differences of angiogenic and inflammatory biomarkers between SDAI, CDAI, ACR, DAS28 and sonographic…
Abstract Number: 1344 • 2017 ACR/ARHP Annual Meeting
Impact of Fibromyalgic RA on Composite Scores; Results from a Longitudinal Study of RA Patients Initiating Bdmard Therapy
Hilde B Hammer¹, Sella A. Provan², Brigitte Michelsen³, Till Uhlig⁴, Jon Lampa⁵ and Tore K Kvien⁶, ¹Rheumatology, Dept. of Rheumatology, Diakonhjemmet Hospital, Oslo, Norway, ²Department of Rheumatology, Diakonhjemmet Hospital, Oslo, Norway, ³Rheumatology, Hospital of Southern Norway trust, Kristiansand, Norway, ⁴Dept. of Rheumatology, Diakonhjemmet Hospital, Oslo, Norway, ⁵Karolinska Institute, Department of Medicine, Rheumatology Unit, Stockholm, Sweden, Stockholm, Sweden, ⁶On behalf of the NOR-DMARD registry, Oslo, Norway
Background/Purpose: The composite scores DAS28, CDAI and SDAI all include number of tender and swollen joints (of 28). Rheumatoid arthritis (RA) patients with tender to…
Abstract Number: 1639 • 2017 ACR/ARHP Annual Meeting
Longitudinal Evolution in a Nationwide Cohort Originally Classified As Mixed Connective Tissue Disease
Silje Reiseter¹, Ragnar Gunnarsson², Jukka Corander³, Johanna Haydon⁴, May Brit Lund⁵ and Øyvind Molberg¹, ¹Oslo University Hospital, Oslo, Norway, ²Department of Rheumatology, Oslo University Hospital, Oslo, Norway, OSLO, Norway, ³Departement of Biostatistics, University of Oslo, Oslo, Norway, ⁴Rheumatology, Vestre Viken Hospital, Drammen, Norway, ⁵Respiratory Medicine, Oslo University Hospital, Oslo, Norway
Background/Purpose: Ever since Mixed Connective Tissue Disease was presented as a distinct entity in 1972, it has been discussed whether MCTD represents an undifferentiated, transient…
Abstract Number: 1879 • 2017 ACR/ARHP Annual Meeting
Majority of Rheumatoid Arthritis Patients in Clinical Remission As Defined By DAS-28, CDAI, SDAI and RAPID-3 Have No Signal on Ultrasound Power Doppler
Allen P. Anandarajah¹, Andreea Coca² and Ralf G. Thiele³, ¹Dept of Rheumatology, Univ of Rochester Medical Ctr, Rochester, NY, ²University of Rochester Medical Center, Rochester, NY, ³Medicine, University of Rochester Medical Center, Rochester, NY
Background/Purpose: Remission in rheumatoid arthritis (RA) is often assessed using the following indices: disease activity scores (DAS-28), clinical disease activity index (CDAI), Simplified Disease Activity…
Abstract Number: 1920 • 2017 ACR/ARHP Annual Meeting
Tacrolimus Induces Remission in Refractory and Relapsing Lupus Nephritis By Decreasing P-Glycoprotein Expression and Function on Peripheral Blood Lymphocytes
Vikas Gupta, Sukesh Edavalath, Mohit Kumar Rai, Harshit Singh, Saurabh Chaturvedi and Vikas Agarwal, Clinical Immunology, Sanjay Gandhi Postgraduate Institute of Medical Sciences, Lucknow, India
Background/Purpose: About 15-30% of Lupus Nephritis (LN) patients do not respond to first-line immunosuppressive therapy. P-glycoprotein (P-gp) mediated efflux of corticosteroids (CS) may contribute to…
Abstract Number: 2017 • 2017 ACR/ARHP Annual Meeting
Prospective Study of Bio-Free Remission Maintenance Using Ultrasonography in Rheumatoid Arthritis Patients: 52-Week Result
Koichi Amano¹, Kazutoshi Aoki², Yoshiaki Kuga³, Koji Nishimura⁴, Hayato Nagasawa⁵, Takuma Tsuzuki Wada⁶, Kenji Takagi⁷, Junji Hayashi⁸, Motohide Kaneko⁹, Ryota Sakai¹⁰, Akiko Shibata¹¹, Kentaro Chino¹¹, Shuntaro Saito¹¹, Ayumi Okuyama¹², Tsuneo Kondo¹², Hirofumi Takei¹² and Toshihide Mimura¹³, ¹Department of Rheumatology and Clinical Immunology,, Saitama Medical Center, Saitama Medical University, Saitama, Japan, ²Aoki Clinic, Saitama, Japan, ³Wakaba Hospital, Sakado, Japan, ⁴internal medicine, Saitama Medical Center, Japan Community Health care Organization, Saitama, Japan, ⁵Nagasawa Clinic, Kawagoe, Japan, ⁶Department of Rheumatology and Applied Immunology, Faculty of Medicine,, Saitama Medical University, Saitama, Japan, ⁷Rheumatology and Clinical Immunology, Higashi-Omiya General Hospital, Saitama, Japan, ⁸Orthopedic Surgery, Niizashiki Chuo General Hospital, Niiza, Japan, ⁹Kaneko Clinic, Kawaguchi, Japan, ¹⁰Microbiology and Immunology, Keio University School of Medicine, Tokyo, Japan, ¹¹Rheumatology and Clinical Immunology, Saitama Medical Center, Saitama Medical University, Kawagoe, Japan, ¹²Department of Rheumatology and Clinical Immunology, Saitama Medical Center, Saitama Medical University, Saitama, Japan, ¹³Department of Rheumatology and Applied Immunology, Faculty of Medicine, Saitama Medical University, Saitama, Japan
Background/Purpose: Recently, a significant number of rheumatoid arthritis (RA) patients can reach low disease activity (LDA) by using biologics such as adalimumab. However biologics therapy…
Abstract Number: 2469 • 2017 ACR/ARHP Annual Meeting
Median Time to Lda Is Shorter in Tocilizumab Combination Therapy with Csdmards As Compared to Monotherapy in Patients with Active Rheumatoid Arthritis and Inadequate Responses to Csdmards and/or TNF Inhibitors: Sub-Analysis of the Swiss and Austrian Patients from the ACT-SURE Study
Ruediger Mueller¹, Winfried Graninger², Páris Sidiropoulos³, Christoph Goger⁴ and Johannes von Kempis⁵, ¹Rheumatology, MD, St. Gallen, Switzerland, ²Rheumatology and Immunology, Medical University of Graz, Graz, Austria, ³F. Hoffmann-La Roche Ltd, South San Francisco, CA, ⁴Roche Austria GmbH, Vienna, Austria, ⁵Rheumatology, Kantonsspital St. Gallen, St. Gallen, Switzerland
Background/Purpose: To analyze efficacy and safety of tocilizumab in patients with rheumatoid arthritis (RA) and an inadequate response to conventional synthetic disease modifying anti-rheumatic drugs…
Abstract Number: 2475 • 2017 ACR/ARHP Annual Meeting
Clinical Remission in Subjects with Rheumatoid Arthritis Treated with Subcutaneous Tocilizumab As Monotherapy or in Combination with Methotrexate or Other Synthetic Dmards: A Real-World Clinical Trial
Raimon Sanmartí¹, Emilio Martín-Mola², João E. Fonseca³, Douglas J. Veale⁴, Alejandro Escudero-Contreras⁵ and Carlos M Gonzalez⁶, ¹Rheumatology Service, Hospital Clínic de Barcelona, Barcelona, Spain, ²Hospital La Paz, Madrid, Spain, ³Rheumatology Research Unit, Instituto de Medicina Molecular, Faculdade de Medicina da Universidade de Lisboa, Lisbon, Portugal, Lisbon, Portugal, ⁴Rheumatology, St. Vincent's University Hospital, Dublin 4, Ireland, ⁵Rheumatology service, IMIBIC/Reina Sofia Hospital/University of Cordoba, Cordoba, Spain, ⁶Rheumatology, Hospital General Universitario Gregorio Marañón, Madrid, Spain
Background/Purpose: the primary objective of this study was to assess the 24-week efficacy and safety of subcutaneous (SC) tocilizumab (TCZ) 162 mg weekly (qw) as…
Abstract Number: 2940 • 2017 ACR/ARHP Annual Meeting
Outcome of Power Doppler Ultrasound-Detected Residual Synovitis in Rheumatoid Arthritis Patients with Clinical Remission: A 1 Year Longitudinal Study with Consecutive Ultrasound Examinations
Gaël Mouterde¹, Cédric Lukas², Nathalie Filippi¹, Gregory Marin³, Nicolas Molinari³, Jacques Morel¹ and Bernard Combe¹, ¹Rheumatology, Montpellier University, Lapeyronie Hospital, Montpellier, France, ²Rheumatology, Lapeyronie Hospital and EA2415 Montpellier University, Montpellier, France, ³Statistics, Montpellier University, Lapeyronie Hospital, Montpellier, France
Background/Purpose: Some studies revealed an association of Power Doppler (PD) ultrasound (US)-detected residual synovitis (PDUSS) and risk of relapse and radiographic progression (RP), in rheumatoid…
Abstract Number: 67 • 2017 Pediatric Rheumatology Symposium
Relapse and Remission in Children with Chronic Non-Infectious Uveitis Treated with Methotrexate and Tumor Necrosis Factor-α Inhibitors
Courtney McCracken¹, Curtis Travers¹, Kirsten Jenkins², Carolyn Drews-Botsch³, Steven Yeh⁴, Sampath Prahalad^1,5 and Sheila Angeles-Han^6,7, ¹Pediatrics, Emory University School of Medicine, Atlanta, GA, ²Children's Healthcare of Atlanta, Atlanta, GA, ³Epidemiology, Emory University School of Public Health, Atlanta, GA, ⁴Ophthalmology, Emory University School of Medicine, Atlanta, GA, ⁵Pediatrics, Emory Children's Center, Atlanta, GA, ⁶Pediatrics, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ⁷Pediatrics, University of Cincinnati, Cincinnati, OH
Background/Purpose: Methotrexate (MTX) and tumor necrosis factor-α inhibitors (TNFi) are common treatments for children with chronic non-infectious uveitis (NIU). Optimal duration of treatment prior to…
Abstract Number: 2528 • 2016 ACR/ARHP Annual Meeting
Predictors of Long Term Survival of Low-Dose Etanercept: An Observational Study
Francesca Ometto¹, Bernd Raffeiner^2,3, Costantino Botsios², Davide Astorri⁴, Lara Friso², Livio Bernardi⁵, Leonardo Punzi⁶ and Andrea Doria², ¹Rheumatology Unit, Department of Medicine - DIMED, University of Padova, PADOVA, Italy, ²Rheumatology Unit, Department of Medicine - DIMED, University of Padova, Padova, Italy, ³Rheumatology Unit, Internal Medicine, General Hospital of Bolzano, Bolzano, Italy, ⁴Rheumatology Unit, Department of Medicine - DIMED, University of Padova, padova, Italy, ⁵Rheumatology Unit, Department of Medicine -DIMED, University of Padova, PADOVA, Italy, ⁶Rheumatology Unit, Department of Medicine DIMED, University of Padova, Padova, Italy
Background/Purpose: The objective of the study was to investigate long-term survival of low-dose etanercept (ETN) (25 mg weekly) and possible predictors of survival. Methods: We…
Abstract Number: 3212 • 2016 ACR/ARHP Annual Meeting
Treat-to-Target in RA: Does Early Simplified Disease Activity Index (SDAI) Remission Lead to Better 5-Year Functional Outcomes Than SDAI Low Disease Activity?
Vibeke Norvang, Elisabeth Lie, Inge C Olsen, Eirik K Kristianslund, Tore K Kvien and Till Uhlig, Dept. of Rheumatology, Diakonhjemmet Hospital, Oslo, Norway
Background/Purpose: The management of rheumatoid arthritis (RA) has evolved considerably during the last couple of decades, with current recommended practice being a treat-to-target approach, involving…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].